CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 141 filers reported holding CATALYST PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 2.99 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $691,276 | -45.4% | 59,134 | -37.3% | 0.00% | -50.0% |
| Q2 2023 | $1,266,801 | -79.4% | 94,256 | -74.5% | 0.00% | -81.8% |
| Q1 2023 | $6,135,546 | -20.1% | 370,057 | -10.4% | 0.01% | -26.7% |
| Q4 2022 | $7,678,731 | +52.9% | 412,835 | +5.4% | 0.02% | +50.0% |
| Q3 2022 | $5,023,000 | -31.1% | 391,504 | -62.3% | 0.01% | +42.9% |
| Q2 2022 | $7,287,000 | -4.0% | 1,039,545 | +13.5% | 0.01% | +16.7% |
| Q1 2022 | $7,590,000 | +2948.2% | 915,525 | +2392.6% | 0.01% | – |
| Q4 2021 | $249,000 | +31.1% | 36,730 | +2.2% | 0.00% | – |
| Q3 2021 | $190,000 | -65.2% | 35,931 | -62.2% | 0.00% | – |
| Q2 2021 | $546,000 | -72.8% | 94,966 | -88.4% | 0.00% | -100.0% |
| Q4 2015 | $2,011,000 | -17.6% | 820,853 | +0.9% | 0.00% | -33.3% |
| Q3 2015 | $2,440,000 | +45.2% | 813,346 | +99.8% | 0.00% | +50.0% |
| Q2 2015 | $1,681,000 | +23.8% | 407,019 | +29.8% | 0.00% | 0.0% |
| Q1 2015 | $1,358,000 | – | 313,523 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANAKA CAPITAL MANAGEMENT INC | 148,281 | $2,458 | 7.14% |
| GABLES CAPITAL MANAGEMENT INC. | 409,080 | $6,782,546 | 4.74% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 10,355,099 | $171,687,541 | 3.83% |
| JW Asset Management, LLC | 563,392 | $9,341,039 | 3.58% |
| Quantedge Capital Pte Ltd | 324,700 | $5,383,526 | 2.10% |
| Paradiem, LLC | 236,628 | $3,923,292 | 1.22% |
| SummerHaven Investment Management, LLC | 100,592 | $1,667,815 | 0.97% |
| Capital Impact Advisors, LLC | 46,096 | $764,272 | 0.94% |
| Yorktown Management & Research Co Inc | 50,000 | $829,000 | 0.89% |
| Seaport Global Advisors, LLC | 15,598 | $258,615 | 0.82% |